Burjeel and Avatrial explore AI cancer-drug research in Abu Dhabi
Their MoU is exploratory and names no committed investment or launch date.
- Publish date: 2026-10-20
- Category: Standards & Policy
- Original source: Emirates News Agency (WAM)
- Reading time: 1 min read
Burjeel Holdings and UK biotech firm Avatrial signed an MoU to explore an AI-enabled cancer-drug discovery ecosystem in Abu Dhabi. The proposed collaboration would combine Burjeel’s regional clinical expertise with Avatrial’s research; no committed investment or launch date was announced.